Antibiotic resistance: current issues and future strategies

Giancarlo Scarafile

DOI: https://doi.org/10.7175/rhc.v7i1.1226

Abstract

The antibiotic resistance (antimicrobial resistance – AMR) and the particular emergence of multi-resistant bacterial strains, is a problem of clinical relevance involving serious threats to public health worldwide. From early this decade, a lot of studies have demonstrated a significant increase in the rates of antibiotic resistance by bacterial pathogens responsible for nosocomial and community infections all over the world. The AMR leads to a reduced drug efficacy in the treatment options available and therefore, to an increase in mortality rates. The original causes of the phenomenon are: environmental factors which favor a mutation of the genetic bacterial inheritance, thereby inhibiting the active ingredient of the antibiotics; unsuitable administering of antibiotics in veterinary, incorrect taking both in hospitals and at home and, lately, lack of investments in the development of new drugs. The alarming epidemiological data prompted the World Health Organization (WHO) in 2011 to coin the slogan "No action today, no cure tomorrow" in order to immediately implement a new strategy to improve the use of available drugs and to accelerate the introduction of new ones through a new phase of research involving private and public institutions. The European Union has stressed that the surveillance is considered an essential factor for an effective response to this problem but it has also highlighted that the results produced have been lower than expectations because of serious shortcomings such as lack of methodological standards, insufficient data sharing and no coordination among European countries. In Italy the situation is much more troubling; in fact, according to the Ministry of Health, 5000-7000 yearly deaths are deemed due to nosocomial infections, with an annual cost of more than 100 million €.These figures explain how the fight against infections is far from being won. The purpose of this review is to analyze the basic causes of the recurrence of the phenomenon, to explain the steps taken by the most important international organizations to face AMR and finally to suggest a possible way to search for new classes of antibiotics.

Keywords

Bacterial pathogens, Antibiotic resistance, Hospitals

Full Text:

HTML PDF

References

  • Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews. Alexandria, VA: Infectious Diseases Society of America, 2004
  • Fauci A. Infectious diseases: considerations for the 21st century. Clin Infect Dis 2001; 32: 675-685; http://dx.doi.org/10.1086/319235
  • World Health Organization (WHO).Antimicrobial resistance: global report on surveillance. Geneva, 2014
  • Alanis A. Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res 2005; 36: 697-705; http://dx.doi.org/10.1016/j.arcmed.2005.06.009
  • McDonald L. Trends in antimicrobial resistance in health care–associated pathogens and effect on treatment. Clin Infect Dis 2006; 42(Suppl 2): S65-71; http://dx.doi.org/10.1086/499404
  • Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance - the need for global solutions. Lancet Infect Dis 2013; 13: 1057-98; http://dx.doi.org/10.1016/S1473-3099(13)70318-9
  • WHO – Regional Committee for Europe. European strategic action plan on antibiotic resistance. EUR/RC61/14, 2011
  • European Centre for Disease Prevention and Control (ECDC). Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net).2013
  • Spellberg B, Powers J, Brass E, et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38: 1279-86; http://dx.doi.org/10.1086/420937
  • ECDC/EMEA. European Centre for Disease Control & European Medicines Agency. The bacterial challenge: time to react. London, UK: 2009
  • Fischbach MA, Walsh CT. Antibiotics For Emerging Pathogens. Science 2009; 325: 1089-93; http://dx.doi.org/10.1126/science.1176667
  • Roberts R, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009; 49: 1175-84; http://dx.doi.org/10.1086/605630
  • Spellberg B, Lewis R, Boucher H, et al. Design of clinical trials of antibacterial agents for community acquired bacterial pneumonia(CABP). Clin Invest 2011; 1: 19-32; http://dx.doi.org/10.4155/cli.10.1
  • Klevens R, Edwards J, Richards C, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007; 122: 160-6
  • Di Massa J, Hansen R, Grabowski H. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-85; http://dx.doi.org/10.1016/S0167-6296(02)00126-1
  • McKenna M. Antibiotic resistance: The last resort. Nature 2013; 499: 394-6; http://dx.doi.org/10.1038/499394a
  • EARSS (European Antimicrobial Resistance Surveillance System), Antimicrobial resistance in Europe. Annual Report Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2010
  • Khanna T, Friendship R, Dewey C, et al. Methicillin resistant Staphylococcus aureus colonization in pigs and pig farmers. Vet Microbiol 2008; 128: 298-303; http://dx.doi.org/10.1016/j.vetmic.2007.10.006
  • Jones T, Kellum M, Porter S, et al. An outbreak of community acquired foodborne illness caused by methicillin-resistant Staphylococcus aureus. Emerg Infect Dis 2002; 8: 82-4; http://dx.doi.org/10.3201/eid0801.010174
  • Wright M. Multi-resistant gram-negative organisms in Maryland: a statewide survey of resistant Acinetobacter baumannii. Am J Infect Control 2005; 33: 419-21; http://dx.doi.org/10.1016/j.ajic.2005.01.009
  • Shin SY, Bae IK, Kim J, et al. Resistance to carbapenems in sequence type 11 Klebsiella pneumoniae is related to DHA-1 and loss of OmpK35 and/or OmpK36. J Med Microbiol 2012; 61: 239-45; http://dx.doi.org/10.1099/jmm.0.037036-0
  • Yigit H, Queenan A, Rasheed J, et al. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing -lactamase KPC-2. Antimicrob. Agents Chemother 2003; 47: 3881-9; http://dx.doi.org/10.1128/AAC.47.12.3881-3889.2003
  • Paterson D. Resistance in Gram-negative bacteria: Enterobacetriaceae. Am J Med 2006; 119: S20-8; http://dx.doi.org/10.1016/j.amjmed.2006.03.013
  • CaiY, Chai D, Wang R, et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012; 67: 1607-15; http://dx.doi.org/10.1093/jac/dks084
  • Queenan A, Shang W, Flamm R, et al. Hydrolysis and inhibition profiles of β- lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob Agents Chemother 2010; 54: 565-69; http://dx.doi.org/10.1128/AAC.01004-09
  • Hooper D. Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists. Clin Infect Dis 2005; 40: 1811-7; http://dx.doi.org/10.1086/430381
  • Papp-Wallace K, Mallo S, Bethel C, et al. A kinetic analysis of the inhibition of FOX-4 β-lactamase, a plasmid-mediated AmpC cephalosporinase, by monocyclic β-lactams and carbapenems. J Antimicrob Chemother 2014; 69: 682-90; http://dx.doi.org/10.1093/jac/dkt434
  • Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34: 482-92; http://dx.doi.org/10.1086/324626
  • Wellington E, Boxall A, Cross P, et al. The role of the natural environment in the emergence of antibiotic resistance in Gram-negative bacteria. Lancet Infect Dis 2013; 13: 155-65; http://dx.doi.org/10.1016/S1473-3099(12)70317-1
  • Orman M, Brynildsen M. Dormancy is not necessary or sufficient for bacterial persistence. Antimicrob Agents Chemother 2013; 57: 3230-9; http://dx.doi.org/10.1128/AAC.00243-13
  • Bahar A, Liu Z, Garafalo M, et al. Controlling Persister and Biofilm Cells of Gram-Negative Bacteria with a New 1,3,5-Triazine Derivative. Pharmaceuticals (Basel) 2015; 8: 696-710; http://dx.doi.org/10.3390/ph8040696
  • D’Costa V, McGrann K, Hughes D, et al. Sampling the antibiotic resistome. Science 2006; 311: 374-77; http://dx.doi.org/10.1126/science.1120800
  • Gaze W, Krone S, Larsson D, et al. Influence of humans on evolution and mobilization of environmental antibiotic resistome. Emerg Infect Dis 2013; 19: e120871; http://dx.doi.org/10.3201/eid1907.120871
  • Guo J, Wang Q, Wang X, et al. Horizontal gene transfer in an acid mine drainage microbial community. BMC Genomics 2015; 16: 496; http://dx.doi.org/10.1186/s12864-015-1720-0
  • Damas P, Canivet J, Ledoux D, et al. Selection of resistance during sequential use of preferential antibiotic classes. Intensive Care Med 2006; 32: 67-74; http://dx.doi.org/10.1007/s00134-005-2805-z
  • European Commission. Ban on antibiotics as growth promoters in animal feed enters into effect. IP/05/1687, Brussels, 2005
  • Karesh W, Dobson A, Lloyd-Smith J, et al. Ecology of zoonoses: natural and unnatural histories. Lancet 2012; 380: 1936-45; http://dx.doi.org/10.1016/S0140-6736(12)61678-X
  • Hollis A, Ahmed Z. Preserving antibiotics, rationally. N Engl J Med 2013; 369: 2474-6; http://dx.doi.org/10.1056/NEJMp1311479
  • Food and Drug Administration(FDA). Summary report on antimicrobials sold or distributed for use in food-producing animals. Washington DC: Department of Health and Human Services, 2011
  • ESAC-Net surveillance. Summary of the latest data on antibiotic consumption in the European Union. November 2015
  • Crombé F, Vanderhaeghen W, Dewulf J, et al. Colonization and transmission of methicillin-resistant Staphylococcus aureus ST398 in nursery piglets. Appl Environ Microbiol 2012; 78: 1631-4; http://dx.doi.org/10.1128/AEM.07356-11
  • Waters A, Contente-Cuomo T, Buchhagen J, et al. Multidrug-Resistant Staphylococcus aureus in US Meat and Poultry. Clinical Infectious Diseases 2011; 52: 1227-30; http://dx.doi.org/10.1093/cid/cir181
  • Battisti A, Franco A, Merialdi G, et al. Heterogeneity among methicillin-resistant Staphylococcus aureus from Italian pig finishing holdings. Vet Microbiol 2010; 142: 361-6; http://dx.doi.org/10.1016/j.vetmic.2009.10.008
  • Bostan K, Aydin A, Ang M. Prevalence and antibiotic susceptibility of thermophilic Campylobacter species on beef, mutton, and chicken carcasses in Istanbul,Turkey. Microb Drug Resist 2009; 15: 143-9; http://dx.doi.org/10.1089/mdr.2009.0894
  • Jensen A, Dalsgaard A, Baggesen D et al.The occurrence and characterization of Campylobacter jejuni and C.coli in organic pigs and their outdoor environment. Vet Microbiol 2006: 116; 96-105; http://dx.doi.org/10.1016/j.vetmic.2006.03.006
  • Garrett N, Devane M, Hudson J, et al. Statistical comparison of Campylobacter jejuni subtypes from human cases and environmental sources. J Appl Microbiol 2007; 103: 2113-21; http://dx.doi.org/10.1111/j.1365-2672.2007.03437.x
  • Pezzotti G, Serafin A, Luzzi I, et al. Occurrence and resistance to antibiotics of Campylobacter jejuni and Campylobacter coli in animals and meat in northeastern Italy. Int J FoodMicrobiol 2003; 82: 281-7; http://dx.doi.org/10.1016/S0168-1605(02)00314-8
  • Juntunen P, Heiska H, Olkkola S, et al. Antimicrobial resistance in Campylobacter coli selected by tylosin treatment at a pig farm. Vet Microbiol 2010; 146: 90-7; http://dx.doi.org/10.1016/j.vetmic.2010.04.027
  • European Food Safety Authority (EFSA) and European Centre for Disease Prevention and Control (ECDC).The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2013. EFSAJ 2015; 13: 3991
  • Center for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. CDC Atlanta, 2013
  • Hecker M, Aron D, Patel N, et al. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 2003; 163: 972-8; http://dx.doi.org/10.1001/archinte.163.8.972
  • Patel J, Rasheed J, Kitchel B. Carbapenemases in Enterobacteriaceae: activity, epidemiology, and laboratory detection. Clin Microbiol News 2009; 31: 55-62
  • Nerandzic M, Donskey C. Triggering germination represents a novel strategy to enhance killing of Clostridium difficile spores. PLoS One 2010; 5: e12285; http://dx.doi.org/10.1371/journal.pone.0012285
  • Lawley T, Clare S, Walker A, et al. Antibiotic Treatment of Clostridium difficile Carrier Mice Triggers a Supershedder State, Spore- Mediated Transmission, and Severe Disease in Immunocompromised Hosts. Infect Immun 2009; 77: 3661-9; http://dx.doi.org/10.1128/IAI.00558-09
  • Riggs M, Sethi A, Zabarsky T, et al. Asymptomatic Carriers Are a Potential Source for Transmission of Epidemic and Non Epidemic Clostridium difficile Strains among Long-Term Care Facility Residents. Clin Infect Dis 2007; 45: 992-8; http://dx.doi.org/10.1086/521854
  • ECDC Surveillance Report. Point prevalence survey of health care associated infections and antimicrobial use in European acute care hospitals 2011-2012.
  • Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013; 19: E23-E30; http://dx.doi.org/10.1111/1469-0691.12070
  • Talbot G, Bradley J, Edwards J, et al. Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-68; http://dx.doi.org/10.1086/499819
  • Cogdill B, Nappi J. Assessment of prescribers’ knowledge of the cost of medications. Ann Pharmacother 2012; 46: 200-7; http://dx.doi.org/10.1345/aph.1Q485
  • Verhoef T, Morris S. Cost-effectiveness and Pricing of Antibacterial Drugs. Chem Biol Drug Des 2015; 85: 4-13; http://dx.doi.org/10.1111/cbdd.12417
  • Falagas M, Fragoulis K, Karydis I. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. PLoS One 2006; 1: e11; http://dx.doi.org/10.1371/journal.pone.0000011
  • Infectious Diseases Society of America. The 10 x ’20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50: 1081-3; http://dx.doi.org/10.1086/652237
  • National Briefing. Washington; More Money Sought to Fight Antibiotic Resistance. 2015:A14
  • World Health Organization Regional Office for Europe. European strategic action plan on antibiotic resistance 2015
  • Niederman M. Principles of appropriate antibiotic use. Int J Antimicrob Agents 2005; 26Suppl 3: 170-5
  • Ball A, Bartlett J, Craig W, et al. Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC. J Chemother 2004; 16: 419-63; http://dx.doi.org/10.1179/joc.2004.16.5.419
  • Finch R, Hunter P. Antibiotic resistance—action to promote new technologies: report of an EU Intergovernmental. J Antimicrob Chemother 2006; 58 Suppl 1: i3-i22; http://dx.doi.org/10.1093/jac/dkl373
  • McDonald L. Trends in antimicrobial resistance in health care–associated pathogens and effect on treatment. Clin Infect Dis 2006; 42(Suppl 2): 65-71; http://dx.doi.org/10.1086/499404
  • Spellberg B, Powers J, Brass E, et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38: 1279-86; http://dx.doi.org/10.1086/420937
  • Lee C , Liang X , Chen X , et al. Species-Specific and Inhibitor-Dependent Conformations of LpxC—Implications for Antibiotic Design. Chem Biol 2011; 18: 38-47; http://dx.doi.org/10.1016/j.chembiol.2010.11.011
  • Granieri L, Miller O, Griffiths A et al. A competition-based assay for the screening of species-specific antibiotics. J Antimicrob Chemother 2009; 64: 62-8; http://dx.doi.org/10.1093/jac/dkp137
  • Pourmand M, Hassanzadeh S, Mashhadi R, et al. Comparison of four diagnostic methods for detection of methicillin resistant Staphylococcus aureus. Iran J Microbiol 2014; 6: 341-4
  • Adaleti R, Nakipoglu Y, Karahan ZC, et al. Comparison of polymerase chain reaction and conventional methods in detecting methicillin-resistant Staphylococcus aureus. J Infect Dev Ctries 2008; 2: 46-50
  • Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005; 56: 20-51; http://dx.doi.org/10.1093/jac/dki171
  • He J, Starr C, Wimley W. A Lack of Synergy Between Membrane-permeabilizing Cationic Antimicrobial Peptides and Conventional Antibiotics. Biochim Biophys Acta 2015; 1848: 8-15; http://dx.doi.org/10.1016/j.bbamem.2014.09.010
  • Rathinakumar R, Wimley W. Biomolecular engineering by combinatorial design and high-throughput screening: small, soluble peptides that permeabilize membranes. J Am Chem Soc 2008; 130: 9849-58; http://dx.doi.org/10.1021/ja8017863
  • Smolinski M, Hamburg M, Lederberg J. Microbial threats to health: emergence, detection, and response. Washington (DC): National Academies Press (US). 2003
  • European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2014.
  • Goel N, Wattal C, Oberoi J, et al. Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. J Antimicrob Chemother 2011; 66: 1625-30; http://dx.doi.org/10.1093/jac/dkr167
  • Ellie J, Goldstein A, Citron D, et al. Comparative In Vitro Activities of GSK2251052, a Novel Boron-Containing Leucyl-tRNA Synthetase Inhibitor, against 916 Anaerobic Organisms. Antimicrob Agents Chemother 2013; 57: 2401-4; http://dx.doi.org/10.1128/AAC.02580-12
  • Sutcliffe J. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 2011; 1241: 122-52; http://dx.doi.org/10.1111/j.1749-6632.2011.06323.x
  • Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-38
  • Barrett J. Can biotech deliver new antibiotics? Curr Opin Microbiol 2005; 8: 498-503; http://dx.doi.org/10.1016/j.mib.2005.08.007
  • Lachmann P. The penumbra of thalidomide,the litigation culture and the licensing of pharmaceuticals. QJM 2012; 105: 1179-89; http://dx.doi.org/10.1093/qjmed/hcs148
  • Tillotson G. Development of new antibacterials: a laudable aim, but what is the value? Clin Infect Dis 2010; 51: 752-3; http://dx.doi.org/10.1086/655956
  • Coenen S, Gielen B, Blommaert A, et al. Appropriate international measures for outpatient antibiotic prescribing and consumption: recommendations from a national data comparison of different measures. J Antimicrob Chemother 2014; 69: 529-34; http://dx.doi.org/10.1093/jac/dkt385
  • Isaacs D, Andresen D. Combating antibiotic resistance: the war on error. Arch Dis Child 2013; 98: 90-1; http://dx.doi.org/10.1136/archdischild-2012-303111

Refbacks

  • There are currently no refbacks.




© SEEd srl